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Summary
Background and purpose: Sonothrombolysis using diagnostic ultrasound (US) in combination
with microbubble (MB) contrast agents is an attractive trial. Superheated perﬂuorocarbon
nanodroplet (SPN), which can turn into MBs upon US trigger, may have advantages in sonothrom-
bolysis. As a preliminary investigation of SPN-assisted sonothrombolysis, we performed a safety
evaluation in vivo.
Method: Twenty male rabbits (2.59± 0.14 kg) were assigned to three groups: the Control group
(n = 6), 2.2mL/kg of physiological saline intravascular (i.v.) injection into auricular vein; the
PL group (n = 8), 25mg/kg of phospholipid-coated SPN i.v.; and the AA group (n = 6), 25mg/kg
of SPN coated with poly aspartic acid derivative i.v. Rectal temperatures were maintained at
39.08± 0.98 ◦C. Neurological evaluation and biochemical blood examinations were performed
at pre-injection, 1, 4, and 7 days after injection. Organ samples including heart, lungs, liver,
spleen and kidneys were harvested after euthanasia.
Abbreviations: US, ultrasound; MB, microbubble; SPN, superheated perﬂuorocarbon nanodroplets; PFC, perﬂuorocarbon; rt-PA,
recombinant tissue-type plasminogen activator; PL, phospholipid-coated; SPN-AA, poly aspartic acid derivative-coated SPN.
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Results: Within an hour after administration of SPNs, both the PL and AA groups showed a
reversible change in respiration. One animal in the AA showed transient nystagmus about 20min
after administration; however, there was no pathological damage. One animal in the PL died
2 days after. No histological damage was found in any organ sample from any of the animals.
Moreover, no signiﬁcant differences were found in the biochemical blood examination between
the PL, AA, and Control groups.
Conclusions: No neurological damage or histological change was found with two SPNs. We will
further investigate the SPN-assisted sonothrombolysis based on the 500-kHz US exposure with
of rt-PA efﬁcacy.
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Figure 1 Images of conversion of SPNs into MBs in vitro. SPNs
turn into MBs in acrylamide gel with exposure to 15 repetition
of 7MHz ﬂash echo. Mechanical index (MI) 0.86, pulse repeti-
tion frequency (PRF) 2Hz, pulse duration (PD) 5min (Aplio XG,
Toshiba, Tokyo, Japan). (a) Phospholipid-coated SPN (Hitachi);
ccess bubble liposome acceleration
© 2012 Elsevier GmbH.
ntroduction
onothrombolysis using diagnostic ultrasound (US) in combi-
ation withmicrobubble (MB) contrast agents is a potentially
roductive means to improve the efﬁciency of rt-PA throm-
olysis [1]. Meanwhile, 500 kHz US exposure with liposome
Bs can accelerate rt-PA thrombolysis efﬁcacy in vitro [2].
uperheated perﬂuorocarbon nanodroplet (SPN) which can
urn into MB upon US trigger, have been studied as a next-
eneration US contrast agent and therapeutic enhancer
3]. Based on these reports, SPNs may have advantages in
onothrombolysis. However, perﬂuorocarbon (PFC) is cur-
ently approved for diagnostic use only because of the
dverse effects including cerebrovascular damage [4,5]. As
preliminary investigation of SPN-assisted sonothromboly-
is, we investigated the possible pharmacological toxicity of
ewly developed SPNs in rabbits as a means of evaluating
he safety of PFCs.
aterials and methods
haracter of SPN
PNs are small in size, typically 200—400 nm in diameter,
nd have compromised sensitivity to US and stability in the
ody [3,6].
We used two types of SPNs for investigation in animals: a
hospholipid-coated SPN, 400 nm in size, that was developed
t the Central Research Laboratory, Hitachi [3,6]; and a SPN
oated with poly aspartic acid derivative, 200 nm in diame-
er, that was developed at the Kanagawa Academy of Science
nd Technology (KAST) [7]. According to previous experi-
ents in rat liver, the SPN dose used in the present study
as assumed to be high enough to generate MBs in vivo by
or 3MHz US [8]. Before this investigation, we had already
onﬁrmed that these two SPNs turn into MBs in vitro (Fig. 1)
nd in vivo (Fig. 2).
xperimental animal groups
e selected rabbits as the subject animals for testing the
afety of PFCs because they are known to have high sen-
itivity to the effects of i.v. injection of PFCs [9]. The
xperimental animal protocol was approved by the animal
esearch committees of Jikei University School of Medicine
Open aTokyo, Japan).
Twenty male Japanese white rabbits (2.59± 0.14 kg)
ere divided into three groups: the Control group (n = 6),
(.2mL/kg of physiological saline i.v. into the auricular vein;
he PL group (n = 8), 25mg/kg of phospholipid-coated SPNs
.v.; and the AA group (n = 6), 25mg/kg of SPNs coated with
oly aspartic acid derivative i.v. The administered dosage
as determined in a previous investigation of rabbit VX
umors in which 30mg/kg of phospholipid-coated SPNs was
njected i.v., revealing severe respiratory side effects in
hree of seven rabbits, including two animals that did not
urvive. In the present study, saline and SPNs were injected
.v. via a 22-G catheter (Angiocath, BD Japan, Fukushima,
apan).
under CC BY-NC-ND license.b) SPN coated with poly aspartic acid derivative (KAST).
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Figure 2 Ultrasonic image of SPNs converted to MB in vivo.
lipid estimation. Statistical analysis was performed with
using Dunnett’s test.
Histological evaluation
All animals were euthanized with i.v. injection of pento-
barbital (20mg/kg) after blood sampling in 7 days. Organ
samples including heart, lungs, liver, spleen and kidneys
were harvested after euthanasia. The brain of neurolog-
ically positive animal was obtained after perfusion with
10% buffered formalin via the right common carotid artery.
Parafﬁn sections were cut at a thickness of 6m. Sections
were stained with hematoxylin and eosin (HE), and Masson
trichrome.
Results
Change of SpO2 after SPN injection
Within 10min after administration of SPN, animals in both
PL and AA group showed a statistically signiﬁcant decrease
in SpO2 with rapid breathing (Fig. 3). However, in all cases,
SpO2 recovered within 1 h. During this investigation, no ani-
mals showed an elevated rectal core temperature.
Neurological ﬁndings after SPN injection
No animals showed signs of paresis, convulsion or anisoco-
ria. One animal in the AA group showed transient horizontal
nystagmus about 20min after SPN administration, and the
duration of nystagmus was 20min (Table 1).
Neuropathological ﬁnding of a nystagmus case in
AA group
There was no neuropathological damage, such as hemor-
rhage, ischemia or any degeneration in brain tissue including
the cerebellum and brain stem (Fig. 4).
Pathological ﬁndings of each organ
One animal in the PL group died 2 days after injection of
SPN. The following description of pathological ﬁndings in
this paragraph and biochemical plasma results from the PL
group includes results from the seven surviving animals.
No histological damage or leukocyte aggregation was
found in any organ sample including the heart, lungs, liver,
kidneys and spleen in any of the animals. No macrophage
hypertrophy or vacuolation was found in the lung, liver or
spleen of any animals (Fig. 5).
Table 1 Neurological ﬁndings after SPN injection.
n Paresis Convulsion Anisocoria NystagmusIntravenously injected SPNs turn into MBs in rat liver with 3MHz
ﬂash echo. 2 kW/cm2 of spatial peak-temporal peak (SPTP), PRF
50Hz, 100 waves (Vevo 770, Visualsonics, Toronto, Canada).
Animal set-up and maintenance
Anesthesia was maintained by i.m. injection of midazolam
(0.04mg/kg) and medetomidine (0.08mg/kg). In a clinical
study, Krafft et al. reported that ﬂu-like symptoms with
light fever and myalgia had occurred when PFC was excreted
from the respiratory system into the air [10]. In our study,
animals were placed on a temperature-controlled plate
and their homeostatic thermal condition was maintained
by measuring rectal temperature (mean± standard devi-
ation = 39.08± 0.98 ◦C) with a rectal digital thermometer
(AW-601H and AW-650H; Nihon Koden, Tokyo, Japan). Ani-
mals were supplied pure oxygen via a face mask (1 L/min).
Measured parameters included arterial blood pressure (ABP)
by cuff and SpO2 with pulse rate (PR) by pulse oximeter
(BSM-2301; Nihon Koden). Animals awakened spontaneously
and were returned to their cages with free access to water
and food on a 12-h light—dark cycle in the animal research
facility at Jikei University School of Medicine.
Neurological evaluation
Neurological evaluation was performed according to a previ-
ous experimental report in which rabbits were injected with
PFC, the neurological check points were the occurrence of
paresis, convulsion, anisocoria, and nystagmus [9].
Blood plasma evaluation
Biochemical blood plasma examination including hepato-
biliary and renal functions, blood lipid were performed at
pre-injection, and 1, 4, and 7 days after injection of SPN.
Blood samples were taken from the auricular marginal vein.
Biochemically estimated items were as follows: total protein
(TP) [g/L], albumin (Alb) [g/L], lactate dehydrogenase (LDH)
[U/L], alanine amino transferase (ALT) [U/L], aspartate
amino transferase (AST) [U/L], -glutanyl transpeptidase (-
GTP) [U/L], alkaline phosphatase (ALP) [U/L], total bilirubin
(T-bil) [mg/dL] for hepatobiliary estimation, blood urea
nitrogen (BUN) [mg/dL], creatinine (Cr) [mg/dL] for renal
estimation, and total cholesterol (Tch) [mg/dL], triglyceride
(TG) [mg/dL], and phospholipid (PL) [mg/dL] for plasma
Control 6 0 0 0 0
PL 8 0 0 0 0
AA 6 0 0 0 1
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Figure 3 Changes of SpO2 after SPN injection. Data are per-
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PN (Hitachi); (b) SPN coated with poly aspartic acid derivative
KAST). * p < 0.05, versus Control group, Mann—Whitney test.
iochemical plasma statistical analysis
n biochemical blood examination, including hepatobiliary,
enal function and plasma lipid, no signiﬁcant differences
ere found between PL, AA, and Control groups (p > 0.05).
utopsy of a dead animal in PL group
n necropsy of the one dead animal in the PL group, dif-
use alveolar damage with deposition of ﬁbrin was apparent.
yaline membrane formation and migration of macrophages
ere clear, suggesting a state of shock. However, a direct
elationship between SPN injection and the histopathologi-
al ﬁndings could not be detected (Fig. 6).
iscussion
anaud initially reported the ‘‘perﬂuorocarbon syndrome’’
s a previously unrecognized hazard of a dialysis-related
linical pathologic event in 2002. He also pointed out that
FC foamwas identiﬁed in bloodmainly in the right ventricle
n autopsied patients, leading to speculation that death was
aused by gas embolism. Oxygen transport characteristic
c
a
o
oigure 4 Photomicrographs of animal with nystagmus in the
A group.
f PFC emulsions are fundamentally different from those
f blood [11]. Nieuwoudt et al. reported that PFC is not
etabolized, but rather is excreted from the respiratory
ystem into the air. In the ﬁrst 24 h, the PFC is cleared
rom the circulation by the mononuclear phagocyte system
ccumulating in the liver, spleen, and bone marrow [12].
sing macroscopic histology, they also demonstrated leuko-
yte aggregation and alveolar macrophage hypertrophy in
everal PFC-injected rats 2 and 4 days after administration.
Canaud et al. (2005) investigated the pharmacological
oxicity of PF-5070 in rabbits [9]. Rabbits were given the
ow (4L/kg) or intermediate dose (40L/kg) exhibited
eneralized malacia of the cerebrum and cerebellum.
otably, one animal showed horizontal nystagmus and
ulmonary infarcts were detected in some rabbits given
he intermediate dose. Neurologically positive animal in
he intermediate and high dose (160L/kg) groups showed
emorrhagic or ischemic damage in the cerebrum and
erebellum. The necrosis was sharply demarcated from
djacent viable tissue, a characteristic morphologic sign
f ischemic infarct. Histopathologic ﬁndings from other
rgans in their study were extensive pulmonary edema,
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RFigure 5 Photomicrographs of each organ in the Control, PL
and AA groups.
hemorrhages and infarction, and disseminated patchy
necrosis of kidney, liver and spleen.
In our study, SpO2 was remarkably decreased in both
the PL and AA groups without histological damage. There
was no macrophage phagocytosis of MBs or necrosis in the
lungs, liver, spleen or kidneys. These phenomena may have
been due to transient pulmonary alveolar occlusion while
intravascular SPNs were present before they were excreted
to the air. This speculation could be extended to the animal
with transient nystagmus in the AA group without cere-
bellum and brain stem damage. According to the study by
Canaud et al. and our study, i.v. administration of PFC in
rabbits might have the potential to cause occlusion within
the vertebrobasilar system [9]. Moreover, one animal in the
PL group that died after injection did not appear to have
leukocyte aggregation or macrophage hypertrophy in the
lungs [12]. However, the causes may also be attributable
to delayed allergic reaction or some other unknown factor
related to SPN injection.
In summary, the side effects of our newly developed SPNs
are reversible respiratory disturbance and transient horizon-
tal nystagmus without permanent neurological deﬁcits, and
biochemical changes in the plasma. One animal in the PL
group died apparently of delayed shock. The most notewor-
thy point in this study is that no pathological damage due to
gas embolism was found in any organs, including the brain
tissue of case that developed temporary nystagmus.
Our next challenges for novel neurological US thera-
pies including sonothrombolysis are further evaluation of
Figure 6 Photomicrograph of lung from one animal in the PL
group that died after injection.
[
[
[29
he safety administration dosages, other kinds of SPNs, and
esearch into transcranial US trigger conditions which can
onvert SPNs into MBs in the cerebrovascular system.
onclusions
o permanent neurological deﬁcit, biochemical changes in
lasma, or histological damage were observed after injec-
ion of the two SPNs in surviving animals.
One animal in the PL group died of delayed shock 2 days
fter injection.
cknowledgments
his study was supported, in part, by the New Energy and
ndustrial Technology Development Organization, Japan.
he authors thank Shiho Sasanuki for her help in performing
he experiments.
eferences
[1] Molina CA, Ribo M, Rubiera M, Montaner J, Santamarina E,
Delgado-Mederos R, et al. Microbubble administration acceler-
ates clot lysis during continuous 2-MHz ultrasound monitoring
in stroke patients treated with intravenous tissue plasminogen
activator. Stroke 2006;37:425—9.
[2] Zenitani T, Suzuki R, Maruyama K, Furuhata H. Accelerating
effects of ultrasonic thrombolysis with bubble liposome. J Med
Ultrasonics 2008;35:5—10.
[3] Asami R, Ikeda T, Azuma T, Kawabata K, Umemura S. Acoustic
signal characterization of phase change nanodroplets in tissue
mimicking phantom gels. Jpn J Appl Phys 2010;49:07HF16.
[4] Canaud B. Performance liquid test as a cause for sudden deaths
of dialysis patients: perﬂuorocarbon, a previously unrecog-
nized hazard for dialysis patients. Nephrol Dial Transplant
2002;17:545—8.
[5] Castro CI, Briceno CJ. Perﬂuorocarbon-based oxygen carriers:
review of products and trials. Artif Organs 2010:622—34.
[6] Kawabata K, Sugita N, Yoshikawa H, Azuma T, Umemura
S. Nanoparticles with multiple perﬂuorocarbon for control-
lable ultrasonically induced phase shifting. Jpn J Appl Phys
2005;44:4548—52.
[7] Shiraishi K, Endoh R, Furuhata H, Nishihara M, Suzuki R,
Maruyama K, et al. A facile preparation method of a
PFC-containing nano-sized emulsion for theranotics of solid
tumor. Int J Pharma 2011;421:379—87.
[8] Asami R, Azuma T, Kawabata K. Fluorocarbon droplets as next
generation contrast agents—–their behavior under 1—3MHz
ultrasound. In: IEEE Proc Int Ultrasnonic Symp. 2009. p.
1294—7.
[9] Canaud B, Aljama P, Tielemans C, Gasparovic V, Gutierrez A,
Locatelli F. Pathochemical toxicity of perﬂuorocarbon-5070, a
liquid test performance ﬂuid previously used in dialyzer man-
ufacturing, conﬁrmed in animal experiment. J Am Soc Nephrol
2005;16:1819—23.
10] Krafft MP, Riess JG. Perﬂuorocarbons: life sciences and biomed-
ical uses. J Polym Sci A 2007;45:1185—98.
11] Barrione P, Mastrone A, Salvo RA, Spaccaminlio A, Grasso L,
Angeli A. Oxygen delivery enhancer: past, present, and future.
J Endcrinol Invest 2008;31:185—92.
12] Nieuwoudt M, Engelbrecht GH, Sentle L, Auer R, Kahn D, van
der Merwe SW. Non-toxicity of IV injected perﬂuorocarbon oxy-
gen carrier in animal model of liver regeneration following
surgical injury. Artiﬁ Cells Blood Substit Immobil Biotechnol
2009;37:117—24.
